Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Totally agree. At least Jonathon is printing something evereday now.
Did anyone listen to broadcast and can explain how to get to it? Thanks.
One brick, another one plus another and Jonathan may be able to build something good after all. Despite my inpatients and criticism I still believe. GO JONATHAN GO!!!
My e-mails are real and I'm not "asking about all kinds of details". If you follow co PRs you shouldn't see any details about anything in any of them, at lease I can't see any. I'm just hoping for some to be truthfully disclosed by now.
Just send another e-mail to Jonathan:
Hi Jonathan,
I'm really worried about overall Co's situation based on departure of 2 key players, not enough or any clear information on dividends, contracts or income. Why is such secrecy?
Is any proof to any contracts or revenues that we should definitely have by know based on prior Co's announcements? If you read the investor boards, and I hope you do, the present situation is killing investment confidence or whatever is left from it. Can we expect a timely quarterly report this time where clear information is given?
Your response will be highly appreciated.
Yours truly,
Solidgold
Nice to see that company is moving in right direction. We need great looking websites for contracts we are working for.
Lem, the broadcast will be in arabic and it will make Jonathan delighted one more time. LOL
Would be delighted to hear it too.
Hi guys, we can post our doubts and questions for as long as we want. The problem is that JB was and is silent on the most of them, and when he speaks he is very fogy or delighted. I don't think we will hear anything new today.
Two major guys leaving us is definitely NOT A GOOD SIGN. And why was it kept as a secret when it is a material fact? What happened with shares they hold? Did they sell before EXTRAORDINARY DIVIDEND?
How much proof from other sources do we have about anything that is going on with this company? JB replied on the most of my e-mails but avoided all important stuff I was asking him including Trevor. And finally, where is Dwudman?
This stock should be plummetting if both of them sold it or still are selling. Is this development the reason why Jonathan got a lawyer?
Doc, the stock is not plummetting now because is PLUMMETED ALREADY. And if you believe in company it's a good time to buy, but the judgement on it is still out.
" a plummet" - I second this.
One positive thing that this stock made it's brought us together. I wish you all GOOD LUCK, GOOD HEALTH and to make many $$$ on this one.
Jonathan, now we need some really good news on signed contracts in our pockets with really clear PR about it.
Hopefully the same speed for implementations for Medify.
Go Jonathan.
UK is moving in right direction.
Electronic staff record now biggest NHS payroll provider
28 Jul 2006 Click to see the
2 reader comments below
The NHS Electronic Staff Record is now installed in over 150 sites across England after being implemented of the largest set of sites yet, and is now the largest payroll provider in the NHS, according to latest figures published by the DH.
The third and largest wave of the project so far was completed this month, with the installation completed in 48 NHS organisations including five sites in North Bristol NHS Trust and seven in NHS Shared Business Services, the finance and payroll public-private joint venture.
There are now a total of 159 organisations using ESR, paying 309,021 staff, making it the largest payroll provider in the NHS.
As well as payroll, the ESR features staff records based on a central server, accessible over a web connection. Employee data will move with the employee, rather than stay within their individual organisation, and both employees and managers will have access to aspects of their record.
The HR functionality gives three levels of access: management - wide access but without the ability to edit; administration, which is full read and write access, although payroll staff are restricted to their sector; and data entry, a "limited subset" of the administration level.
All changes that are made to an electronic staff record are audited and previous versions are kept; in this way employment history is kept for each member of staff.
Users can also use reporting tools from the ESR; for example, equal opportunity monitoring and recruitment sources can be monitored for new employees. Reasons for staff leaving can also be aggregated, which is named as one potential benefit to NHS organisations as it can highlight problem areas.
"ESR will interface with electronic recruitment solutions," said Maureen Edwards, senior user and ESR human resources director. "It is interfaced with NHS Jobs, and can on request, be interfaced with other e-recruitment services."
The implementation of the ESR is being undertaken by the DH working with a group headed by McKesson, with Oracle providing the software and IBM the hardware.
Ros Penny, head of development and ESR at Royal Devon and Exeter NHS Foundation Trust, who was involved in the first wave of implementations at the beginning of this year, told EHI that it was important not to see it as an IT project but as a change of working practices.
Identifying who is responsible for the change is extremely important, she said.
"One of the things that was difficult for us was that the payroll department reports to the finance director. There's doubt about who really owns the system."
Another early issue was training and literature, she added. Training to staff had initially been given on a best-case only scenario, and there was no early knowledge base. However, Penny said, McKesson was receptive to feedback. "To be fair, since we went through this, McKesson has developed electronic learning tools and they have developed online user guides which are excellent."
Hands-on training is given in a 'dummy' environment with 350 records, containing all ESR modules as part of TPly, an 'education practice environment'.
"Our implementation has been very good," said Penny. "I think that the quality of the implementation comes down to the amount of effort put in by the trust. There's no doubt that ESR is a catalyst for change."
The DH hopes that the project will smooth the transition to the use of shared services, and will improve business efficiency and reporting. On a trust level, said Penny, the system will be used to introduce rostering and reduce overtime, and improve managerial responsibility for staff.
The system will be fully installed across the NHS in England and Wales in five more waves, with the final implementations happening at the beginning of 2008.
Links
ESR homepage
© 2005 E-HEALTH-MEDIA LTD. ALL RIGHTS RESERVED.
I hope we all make money.
Per Jonathan:
The first roll out site is for approximately 2500 users ($85 per customer per month for two years with an expected revenue stream of $5.1m).
I assume what it says.
Feel more and more optimistic!!!
With PPS > $1 will feel great!!!
Hot Stocks to Watch for Thursday, August 03, 2006: Genesis Partners Raising Profit Projections Upwards!
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.
WESTON, FL, Aug 03, 2006 (MARKET WIRE via COMTEX) -- TheSUBWAY.com announces the following stocks to its Hot Stocks List: Genesis Technology Group, Inc. (OTCBB: GTEC), NVIDIA Corporation (NASDAQ: NVDA), JDSU (NASDAQ: JDSU), Ericsson (NASDAQ: ERICY)
Genesis Technology Group, Inc. (OTCBB: GTEC) has announced that he progress of Lotus Pharmaceuticals and Gold Horse International, Genesis' equity partners, is excellent. In less than 90 days, both companies could be trading, thus dramatically increasing the net asset value of Genesis. Genesis could have an admirable equity position in five to 10 new public companies within the next nine months in addition to its six current investments.
Genesis Technology Group's pharmaceuticals partner in Beijing, Lotus Pharmaceuticals, Inc., has commenced programs to increase its 2006 revenues above $20 million with about 15% in net profits, and to establish Lotus as a national brand in China. New facilities, manufacturing capability, and four drugs scheduled to come to market in the fall all contributed to the increased forecasts. Lotus has no debt, company revenues for the first six months of 2006 exceeded $16 million. This is an increase of 100% from 2005. To date, 2006 profit margins reached 27%. Based on these revised projections and its significant equity stake in Lotus, Genesis estimates its own net gain could exceed $2 million.
Genesis Technology Group's real estate development partner in Hohhot, Inner Mongolia, Gold Horse International Inc., has undertaken major new construction projects in the region that could increase its 2006 revenues to over $50 million and profits to above $7 million. Genesis holds a significant equity position in Gold Horse, in addition to receiving management and consulting fees. Based on these revised projections, Genesis estimates its net gain could exceed $2 million.
Other stocks highlighted include NVIDIA Corporation (NASDAQ: NVDA): Hot Stocks List, up 7% on 12 million shares, JDSU (NASDAQ: JDSU): Hot Stocks List, up 1% on 21 million shares, Ericsson (NASDAQ: ERICY): Hot Stocks List, up 1% on 1 million shares.
"A few disappointing earnings releases and some disparate economic data have done their part to stall the market's advance, and political developments abroad have kept investors cautious. But overall tame inflation numbers, though rising over the past few months, solid growth in the domestic economy, and lower unemployment are buffeting the averages from below." More is available at: http://www.thesubway.com.
TheSUBWAY.com's Daily Stock Updates:
TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com.
All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated one million restricted shares for GTEC. CRG has received additional compensation of ten thousand dollars, and has purchased two hundred ten thousand shares in the open market and has also received six hundred thousand common shares and four million four hundred thousand restricted shares as past compensation. CRG intends to sell its shares. CRG has sold approximately all but two million five hundred thousand restricted GTEC shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
CONTACT:
Chuck Tamburello
Phone: 954-217-8555
Fax: 954-217-1500
SOURCE: TheSUBWAY.com
Copyright 2006 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Financial Services:Investment Opinion
Business/Finance: General:Investment Opinion
Search for Dun & Bradstreet reports on this company.
Feel more and more optimistic!
Got verification from Jonathan:
From: Solidgold
Sent: 02 August 2006 19:15
To: Jonathan Bryant
Subject: Income
Hi Jonathan,
Could you please verify again how much of $85 will go directly to Medify and how much will go to partners?
Thanks,
Solidgold
-----------------------------------------------------------------
78% to Medify.
Purple, good point. Italy and whoever else should kick income to Medify. I hope that everyone understands that I simply copy Jonathan's e-mails to me for everyone's benefit w/o adding my personal opinions to his e-mails.
I do appreciate that Jonathan is answering most of my e-mails, but not all of them.
Personally I'm cautiously optimistic with many quetions still to be answered by Medify. But the best answer would be a proven signed contract with all numbers disclosed w/o any questions needed.
Clancy, the schedule to the float
will be announced as soon as Jonathan announces it.
Thanks Lem. Good times are coming for us!!!
Great info, Lem. Could you provide the link please?
It would be nice to see how they arrive to this target nunber.
"Straight from Jonathan's mouth" :
Sent: 02 August 2006 15:35
To: Jonathan Bryant
Subject: Latest news
Hi Jonathan,
Congrats with your latest news!
Could you please clarify if all $85 per Mo per customer belong to MFYS?
Also, is Mo charge will be the same for all countries?
Best of luck!
Solidgold
-----------------------------------------------------------------
Solidgold,
You are correct in your assumptions. There will be a standard pro-rata price for all countries.
The gross margins for Medify, now we have our own in house product, are approximately 78%.
Everything is all systems go and we don't need luck, the product the float and the end result is being delivered as per my plan. This is the reason I wanted to make sure everybody understands that if you do the maths, this has the potential to become a billion dollar company starting on the 1st of September.
Jonathan.
We all hope it would be and more.
$85 x 12 = $1020 per user per year.
Genesis Management Offers Mid-Year Review From New York Conference
Wednesday August 2, 7:00 am ET
BOCA RATON, Fla., Aug. 2, 2006 (PRIMEZONE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News) Management released a mid-year review of the Company's accomplishments while in attendance at ``The Reverse Merger Conference 2006,'' sponsored by Deal Flow Media at The Hilton Hotel in New York City.
Since its last Quarterly Report, the Company has:
-- Completed the SEC audit of its partner company, Lotus
Pharmaceuticals, Inc. Beijing-based Lotus should be publicly
trading near term, and Genesis will maintain a significant equity
position in this company. The Lotus website, http://www.LotusEast.com, is
still under development, but accessible for public preview.
-- Advanced the due diligence process of its other partner company,
Gold Horse International, Inc. Like Lotus, Richardson & Patel law
firm, headquartered in Los Angeles, is serving as the securities
counsel. Once its audit is completed, Gold Horse could be publicly
trading before year end, and Genesis will maintain a significant
equity position in this company.
-- Benefited from its Beijing Media Event on May 23rd, by sourcing
several new partner company candidates. The Genesis Equity
Partners' (GEP) initiative, which can be studied at http://www.GEP888.com,
received broad national press coverage and support in China.
"Important policy changes by the Ministry of Commerce, to be
announced in the coming days, could actually benefit GEP and may
even lessen our U.S. current competition," observed Dr. Shaohua
Tan, Director of China Operations.
-- Attended "The Reverse Merger Conference 2006," sponsored by Deal
Flow Media at The Hilton Hotel in New York City on July 20th. GEP
met with several public shell sources to advance its partnering
program with qualified Chinese companies. GEP anticipates
additional contracts before year end.
-- Continued its "merger search" for Genesis, and remains committed to
selecting a qualified candidate that would substantially add value
to the GTEC shareholders' and stake holders' investments. "We have
been approached by many companies about merger opportunity or
acquisition of Genesis. With our cash position, low overhead, and
appreciating equity basket of marketable securities, Genesis must
move forward cautiously and judiciously before committing to any
merger," stated President Kenneth Clinton.
-- Prepared for release its third quarterly report (10SBQ), and
management remains satisfied that its unique partnering program
will provide positive and sustainable returns to the Genesis
shareholders. The SEC filing will occur before the August
deadline.
In summary, Genesis management contends that the Company has advanced constructively and continues on a track of profitability and sustainability. ``China shall always remain a land of huge opportunities and commensurate challenges,'' commented CEO Gary Wolfson. ``It is not for the faint of heart or impatient of attitude. For those who believe in China's future as we do, the rewards can be great, but it will take time and commitment to reach our goals.''
CHANGE OF ADDRESS NOTICE: Effective July 1, 2006, the main office for all China operations moved to Oriental Plaza, Level 6, Tower W2, One East Chang An Avenue, Dong Cheng District, Beijing 100738, People's Republic of China.
About Genesis Technology Group, Inc.
Genesis Technology Group, Inc. is a business development firm that fosters bilateral commerce between Western and Chinese companies. Genesis has created successful profit centers in product development, manufacturing, distribution, joint ventures and operational services. The Company has offices in the United States and China. A majority owned subsidiary of Genesis, Genesis Equity Partners, LLC (``GEP'') assists Chinese and Western companies in formulating strategies to increase equity value, while targeting Western stock exchanges as a source of capital and shareholder support. The core strength of GEP management is creating a first rate plan to create investor awareness and bring in long-term individual and institutional investors. GEP should create liquidity in the stock and gain investor awareness by using tested channels of communications by cogently articulating the companies' stories. GEP has built successful channels with expertise in screening and selecting Chinese companies that possess solid business histories and professional management, and North American public companies and shells that possess a shareholder base and a history of auditing and filing, as required by the U.S. Securities & Exchange Commission. For more information, visit http://www.genesis-technology.net and http://www.GEP888.com
Safe Harbor Statement
Certain statements set forth in this press release constitute ``forward-looking statements.'' Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words ``estimate,'' ``project,'' ``intend,'' ``forecast,'' ``anticipate,'' ``plan,'' ``planning,'' ``expect,'' ``believe,'' ``will likely,'' ``should,'' ``could,'' ``would,'' ``may'' or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
If $85 per Mo per user goes to Medify only than income should be huge!
Medify has the approved connection to NHS' N3, the secure national IT network and has contracts to provide the service to NHS Healthcare professionals, which will now roll out over the next 12 months. As the only provider to offer the service Medify is set to achieve significant revenues starting on the 1st of September 2006.
Therefore for every 1% market penetration, the revenue for Medify is $5.1m per annum.
Of further importance is that UK Healthcare professionals represent approximately 10% of the overall European market and approximately 1% of a total global market of 59 million professionals (potential users).
Medify Solutions Limited (Pink Sheets MFYS) explains the sales potential for UK Remote access market
Wednesday August 2, 10:00 am ET
GATESHEAD, UK, Aug. 2 /PRNewswire-FirstCall/ - On the 1st September 2006, Medify Solutions Limited will roll out its 'remote access to patient notes' product, MedifyRemote, to its National Health Service (NHS) customers. The first NHS site, as published previously, will be in Doncaster in the north of England.
This site is leading the way for the rest of the UK in terms of development and user testing of the powerful Medify Remote live product, which will bring many benefits for patients and users in terms of greater efficiency and more accurate transfer of information.
Operating through its N3 approved secure connection to the NHS patient database; Medify will begin the roll out to its live NHS customers. This will be coordinated through corporate partners who are providing the patient record software and airtime connection to the NHS.
The sales potential for Medify Remote is significant. For ease of understanding, the product will be offered to the customer at a monthly charge in the region of $85 per month. In the UK there are over 500 000 healthcare professionals, the primary target user. Thus the market for Medify in the UK alone is $510m per annum (85 x 500 000 x 12).
Therefore for every 1% market penetration, the revenue for Medify is $5.1m per annum.
Medify has the approved connection to NHS' N3, the secure national IT network and has contracts to provide the service to NHS Healthcare professionals, which will now roll out over the next 12 months. As the only provider to offer the service Medify is set to achieve significant revenues starting on the 1st of September 2006.
Of further importance is that UK Healthcare professionals represent approximately 10% of the overall European market and approximately 1% of a total global market of 59 million professionals (potential users).
Contact : press@medifysolutions.com
Company website : www.medifysolutions.com
This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements. The words "estimate," "project," "intends," "expects," "believes," and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbour" provisions of the Private Securities Litigation Reform Act of 1995. For a more complete description of these and other risk factors that may affect the future performance of Medify Solutions Limited, see "Risk Factors" in the Company's Annual Report on Form 10-KSB and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made and the Company undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.
--------------------------------------------------------------------------------
Source: Medify Solutions Ltd.
Hello everyone. I'm holding my shares and divs. Thanks Mick.
Clancy, ones again you leave me nothihg to add.
NONE!!! Disappointment but no surprise on very low valume and not much interest in Medify's dividends = low PPS.
Jonathan, we need some beef.
what should be within next month if Jonathan is cooking.
Buy me out @9.50 now.
No byuout at $10, just 2:1 forward split would do it for me.
Of course backed up by revenues from UK, Italy, Spain, Canada,
Asia and etc.
If dividend will trade and hold around $1 than MFYS should trade for about the same, so 13c and < 50c is really well under value. IMHO. Go Medify!!!!!! Good luck to all.